Narcolepsy Market Scope And Analysis

  • Report Code : TIPRE00003326
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 153
Buy Now

Narcolepsy Market Scope, Analysis, and Trends by 2027

Buy Now

Narcolepsy Market Report Narcolepsy Market Size and Share Narcolepsy Market Scope and Analysis

Narcolepsy Market Report Scope

Report Attribute Details
Market size in 2018 US$ 2.03 Billion
Market Size by 2027 US$ 4.54 Billion
Global CAGR (2018 - 2027) 9.5%
Historical Data 2016-2017
Forecast period 2019-2027
Segments Covered By Type
  • Narcolepsy with Cataplexy
  • Narcolepsy without Cataplexy
  • Secondary Narcolepsy
By Product
  • Central Nervous System Stimulants
  • Sodium Oxybate
  • Antidepressants
By Distribution Channel
  • Hospital Pharmacies and Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Bioprojet
  • Teva Pharmaceutical Industries Ltd
  • Jazz Pharmaceuticals Inc
  • Graymark Healthcare Inc
  • Arena Pharmaceuticals Inc
  • Shire Acquired by Takeda
  • Ligand Pharmaceuticals Inc
  • Novartis AG
  • Mylan N V

    • Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. The market share is anticipated to flourish with the development of new innovative products by market players. Some of the market participants offering products are Teva Pharmaceutical Industries Ltd; Jazz Pharmaceuticals plc; Arena Pharmaceuticals, Inc; Graymark Healthcare, Inc; Novartis AG; Takeda Pharmaceutical Company Limited; Mylan N.V.; BIOPROJET; Shionogi & Co., Ltd; and Ligand Pharmaceuticals, Inc.